Stevanato Group S.p.A. (STVN) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. At $18.01, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Weak overall score: 4.9/10.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two... Read more
Sell if holding. At $18.01, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Weak overall score: 4.9/10. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: aggressive.
Recent Developments — Stevanato Group S.p.A.
Latest news
- Stevanato Group (NYSE:STVN) Sees Unusually-High Trading Volume - Should You Buy? - MarketBeat — MarketBeat neutral
- Stevanato S p A : Report on Remuneration Policy and Practices 2026 - marketscreener.com — marketscreener.com neutral
- Stevanato S p A : Report of the Audit Committee to the Shareholders on the Activities Carried Out in the Financial Year — marketscreener.com neutral
- Stevanato Group (STVN) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance — Yahoo Finance positive
- Stevanato Group Files Form 6-K Detailing Q1 2026 Results Presentation - TipRanks — TipRanks neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $18.01, A.R:R 1.3:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Weak overall score: 4.9/10. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $16.75. Score 4.9/10, moderate confidence.
Take-profit target: $21.60 (+19.9% upside). Prior stop was $16.75. Stop-loss: $16.75.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.5); Weak overall score: 4.9/10; Weak growth.
Stevanato Group S.p.A. trades at a P/E of 30.0 (forward 21.1). TrendMatrix value score: 4.7/10. Verdict: Sell.
17 analysts cover STVN with a consensus score of 4.2/5. Average price target: $25.
What does Stevanato Group S.p.A. do?Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide...
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass converting machines; and after-sales services, such as line optimization and line conversions, training, logistics, spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug products, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.